Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) EPS (Weighted Average and Diluted) (2021 - 2026)

PharmaCyte Biotech (PMCB) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.17 as the latest value for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) rose 61.36% to -$0.17 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.12 through Jan 2026, down 251.35% year-over-year, with the annual reading at $3.19 for FY2025, 277.22% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was -$0.17 at PharmaCyte Biotech, up from -$1.24 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $1.9 in Q3 2024, with the low at -$1.24 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.11, with a median of -$0.17 recorded in 2026.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 778.57% in 2024, while the deepest fall reached 3200.0% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.09 in 2022, then plummeted by 134.85% to -$0.21 in 2023, then plummeted by 84.52% to -$0.39 in 2024, then plummeted by 217.95% to -$1.24 in 2025, then surged by 86.29% to -$0.17 in 2026.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.17, -$1.24, and -$1.23 for Q1 2026, Q4 2025, and Q3 2025 respectively.